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The opioid agonist codeine and antagonist naltrexone do not
affect voluntary suppression of capsaicin induced cough
in healthy subjects
H.A. Hutchings, R. Eccles
The opioid agonist codeine and antagonist naltrexone do not affect voluntary suppres-
sion of capsaicin induced cough in healthy subjects.  H.A. Hutchings, R. Eccles.  ERS
Journals Ltd 1994.
ABSTRACT:  Opioids exert an analgesic action by mimicking the effects of endoge-
nous neurotransmitter substances in the central nervous system.  Opioids are widely
used as antitussives, and it is reasonable to assume that endogenous opioids are
involved in the control of cough.  In order to investigate this hypothesis, a parallel
design study was carried out to examine the effects of 50 mg codeine (opioid ago-
nist), 50 mg naltrexone (opioid antagonist) and placebo on capsaicin-induced cough
in 80 healthy volunteers (mean age 25 yrs).
Volunteers received two capsaicin challenge units (each consisting of five inhala-
tions of different concentrations of capsaicin, 0.00–3.33×10-4 M).  On one challenge
unit subjects were instructed to suppress cough, and on the other challenge unit
subjects coughed freely.  Coughs were recorded on a tape cassette player and later
played back into a pen recorder to produce integrated sound traces.
The number of coughs in the suppression challenge unit was significantly reduced
in all three treatment groups compared to that recorded in the non-suppression
challenge unit.  Comparisons between the three treatment groups showed that there
was no statistical difference between the three groups both before and 90 min after
treatment for the total coughs in the suppression challenge unit and for the total
coughs in the non-suppression challenge unit.
These results demonstrate that capsaicin-induced cough can be voluntarily sup-
pressed, but that both suppressed and non-suppressed cough were unaffected by
treatment with codeine, naltrexone or placebo.  These results do not provide any
support for the hypothesis that capsaicin-induced cough is influenced by endoge-
nous opioid substances.
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Opioids possess many pharmacological properties, with
analgesia being the most notable.  Some opioid sub-
stances, such as codeine, are also widely used as anti-
tussive agents in cough medications, and they are believed
to exert a relatively specific central inhibitory action on
the "cough centre" in the medulla, without causing res-
piratory depression.  When used as an analgesic, codeine
behaves as an opioid agonist, and interacts with specific
opioid receptor sites in the central nervous system that
are also the site of action of a number of endogenous
opioid neurotransmitters, such as endorphins and enkep-
halins [1].  It is reasonable to assume that the antitus-
sive activity of codeine may also be related to this agonist
action at central endogenous opioid receptor sites, and
that the central component of the cough reflex may be
influenced both by opioid agonists and antagonists.
Evidence for the involvement of endogenous opioids
in the cough reflex is provided by recent research [2],
where it was shown that beta-endorphin, a potent endoge-
nous opioid peptide is synthesized in the nucleus trac-
tus solitarius (NTS).  The presence of beta-endorphin
producing neurons is consistent with the idea that beta-
endorphins regulate respiration, but the NTS is also the
first central synapse of primary afferent fibres that origi-
nate from airway receptors [3].  It has been stated [4]
that, in addition to regulating respiration, the NTS plays
an important role in the regulation of the cough reflex.
Thus, endogenous opioids may have a significant anti-
tussive effect, and they may be involved in the volun-
tary suppression of cough.  If this is the case, an opioid
antagonist might be expected to alter the action of endo-
genous opioids on the cough reflex and to enhance cough,
especially when these endogenous opioid systems are
activated.
In a previous paper [5], we demonstrated that cough
induced on inhalation of capsaicin could be voluntarily
suppressed, and in the present study, we proposed to
investigate the effects of the opioid agonist codeine, and
the opioid antagonist naltrexone on the voluntary sup-
pression of capsaicin-induced cough.  This model of vol-
untary cough suppression may be particularly useful in
studying the effects of an opioid antagonist on cough, as
the effects of opioid antagonists on endogenous opioids
can only be demonstrated when the endogenous opioid
system is activated [1].
The hypothesis to be tested in the present study is that
endogenous opioids are involved in the control of cap-
saicin-induced cough and that an opioid agonist, such as
codeine, would be expected to reduce cough, whilst an
opioid antagonist, such as naltrexone, would be expec-
ted to increase cough, especially during the voluntary
suppression of cough.
Subjects and methods
Subjects 
Volunteers were selected from the student and general
population of Cardiff, in response to advertisements for
healthy volunteers.
Eighty volunteers presented for the study, 28 males
and 52 females, with an average age of 25 yrs (range
18–49 yrs).  Subjects read the subject information form,
completed a questionnaire concerning their history and
signed the informed consent.  Each volunteer was then
examined by the clinician to determine their state of
health and suitability for the trial.  Volunteers were fas-
ted on the morning prior to the study.
Volunteers were required to fulfil certain criteria before
they were included in the study [5].  Volunteers were
also excluded during the study if they failed to cough on
capsaicin challenge, or coughed in response to saline (in
the baseline non-suppression challenge).
The trial was approved by the local hospital Medical
Ethics Committee.
Methods
The volunteer was seated in a comfortable chair fac-
ing a monitor screen.  They were instructed to watch the
monitor screen carefully and to carry out the instructions
as the appropriate box was illuminated.  One of two com-
mands was lit up:  "Please do not cough" or "Just relax
and cough if you wish".
The study was a parallel group design and involved
inhalation of single breaths of capsaicin (Cookson Chemi-
cals, UK) in 10% ethyl alcohol in normal sterile saline
solution.  Varying concentrations (0.00, 1.00×10-5,
3.33×10-5, 1.00×10-4 and 3.33×10-4 M) were delivered by
a breath-activated dosimeter (P.K. Morgan, UK).  The
mass median aerodynamic diameter (MMAD) of the
delivered particles was 2–5 µm.  The period of inhala-
tion was set at 1 s.  The solutions were made up daily
from stock solutions (which were made up weekly), and
were stored in a refrigerator at a temperature of 0–6°C.
The nebulized solutions were delivered to the volunteers
at room temperature.
Volunteers were given training and instructions as to
the appropriate technique for inhalation of the nebulized
solutions, and were given a nebulized saline solution on
which to practice the technique.
Volunteers received all five concentrations of capsaicin.
Each set of five inhalations was defined as a challenge
unit.  The solutions were administered in random order,
with an interval of 60 s between each inhalation.  Two
capsaicin challenge units were given 5 min apart.  On
one of these challenge units the volunteer was given the
instruction "Just relax and cough if you wish", and was
able to cough when necessary, and on the other chal-
lenge unit, the volunteer was given the instruction "Please
do not cough", in which case the volunteer would try to
suppress cough for a period of up to 30 s.  Volunteers
were instructed prior to the study not to hold their breath
on this command, and to try to maintain normal breath-
ing.  After the 30 s period of cough suppression the vol-
unteer was given the instruction "Just relax and cough
if you wish".  The order of the challenge units was ran-
domized between subjects and between treatment groups,
i.e. some volunteers were asked to suppress cough on
the first challenge unit and some were asked to suppress
cough on the second challenge unit.
After receiving two challenge units, each volunteer
received a randomized treatment, which consisted of mat-
ched capsules of either codeine (50 mg), naltrexone (50
mg), or placebo.  Both the volunteer and the investiga-
tor were blind as to which treatment had been adminis-
tered.
Ninety minutes after administration of the treatment,
the volunteer received a further two challenge units of
capsaicin.  The order of the challenge units was the
reverse of that which occurred at baseline.
Coughs were recorded by means of a Sony TCM 84V
V.O.R cassette-corder (Taiwan) for a period of 30 s after
each non-suppression challenge and a period of 60 s after
each suppression challenge.  Recorded tapes were later
played back into a Datagraph (UK) pen recorder, set at
a time constant of 0.02 s to produce integrated pen recor-
ded traces.  Coughs were counted from the pen recorder
trace according to the method used in a previous study
[5].
Volunteers were not permitted to eat or drink during
each challenge period, but were asked to drink a glass
of water between each challenge unit.
A "Macintosh" "Statview IV" package was used to cal-
culate the statistics.  Results are expressed as median
(with interquartile range).  Nonparametric Freidman tests
were used to determine the differences between the three
treatment groups at baseline and 90 min with respect to
the number of coughs at each concentration and the total
number of coughs in each challenge unit.
Changes in cough response due to codeine, naltrexone
or placebo were obtained by subtracting the baseline total
cough response (i.e. the sum of the coughs from all cap-
saicin inhalations in a challenge unit) from the total num-
ber of coughs 90 min after treatment.  Changes in the
cough responses were obtained for the non-suppression
and suppression challenges.  Wilcoxon signed rank
tests were then used to determine differences within each
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treatment group between the baseline and 90 min chal-
lenges.  Values of p<0.05 were considered to be signifi-
cant.  A retrospective power calculation at a power level
of 80% (5% significance level) found that 27 subjects
were required in each group to detect a 30% change in
total cough counts.
Results
From the 80 subjects entered into the study, seven were
excluded from the analysis.  Five of these subjects had
a total cough count of ≥30 at baseline and were, there-
fore, considered to be hypersensitive to capsaicin.  The
remaining two subjects suffered from nausea and vomi-
ting as a result of treatment (1 codeine, 1 naltrexone)
and were withdrawn from the study prior to the 90 min
challenge.  Of the remaining 73 subjects, the distribu-
tion of the treatments was:  codeine:  27 (at baseline 14
received non-suppression challenge first and 13 received
suppression challenge first); naltrexone: 25 (14 non-
suppression first, 11 suppression first);  and placebo:  21
(10 non-suppression first and 11 suppression first).
Non-suppression capsaicin challenge
At baseline, a cough dose response relationship was
found on administration of increasing concentrations of
capsaicin in response to the instruction "Just relax and
cough if you wish".  These results correspond to those
obtained in a previous study [5].  Similarly, 90 min after
treatment, dose response relationships were again seen.
There was no significant difference between any of
the three treatment groups at any concentration of cap-
saicin at baseline (p corrected for ties >0.48 for all con-
centrations), or 90 min after treatment (p corrected for
ties >0.18 for all capsaicin concentrations).
Total coughs were calculated for each subject in the
three treatment groups by adding the number of coughs
produced at each concentration of capsaicin in the non-
suppression challenge.  Table 1 shows the median total
number of coughs at baseline and 90 min after treatment
in the non-suppression challenge in the three treatment
groups.  No significant difference was found for the total
number of coughs between the three treatment groups at
baseline (p corrected for ties=0.81), or at 90 min (p cor-
rected for ties=0.78).
Changes in cough response following treatment 
Changes in cough responses between the baseline and
treatment non-suppression challenges were calculated for
the placebo, codeine and naltrexone groups and are illus-
trated in figure 1.  The total number of coughs at 90 min
was generally less than that at baseline in all three treat-
ment groups as shown in table 1.  There were 14 out of
21 placebo, 19 out of 27 codeine and 18 out of 25 nal-
trexone subjects who showed a reduction in the total
number of coughs in the non-suppression challenge 90
min after treatment, compared to baseline.  Wilcoxon
signed rank tests were used to compare the total num-
ber of coughs at baseline and 90 min in each of the treat-
ment groups, and tied p-values were 0.07, 0.01 and 0.17
for placebo, codeine and naltrexone, respectively.  Codeine
was the only treatment group which showed a signifi-
cant reduction from baseline; however, when this was
compared across groups there was no significant differ-
ence between codeine and placebo groups.
Suppression capsaicin challenge
Following the instruction "Please do not cough", the
number of coughs both at baseline and 90 min during
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Table 1.  –  Median total number of coughs (with interquartile range in parenthesis) for
each treatment group
Challenge Placebo Codeine Naltrexone p-value
Baseline
Non-suppression 12.0 (6.3–17.0) 9.0 (4.0–17.5) 9.5 (6.0–15.0) 0.81
Suppression 0.0 (0.0–6.0) 1.0 (0.0–4.0) 0.5 (0.0–4.0) 0.78
Post-treatment*
Non-suppression 10.0 (5.5–13.5) 8.0 (4.0–13.8) 9.0 (3.8–14.3) 0.78
Suppression 0.0 (0.0–6.0) 0.0 (0.0–2.2) 0.0 (0.0–3.0) 0.43
Total coughs were calculated by adding the number of coughs produced at each concentration
of capsaicin within the different challenge units.  *:  90 mins post-treatment.
Placebo Codeine Naltrexone
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Fig. 1.  –  Changes in the number of coughs to capsaicin after treat-
ment in the non-suppression challenge.  Data represent the changes
in cough response in the placebo, codeine or naltrexone treated
groups, obtained by subtracting the total number of coughs in the non-
suppression challenge at baseline from the total number of coughs in
the non-suppression challenge 90 min after treatment.
the suppression challenge was significantly reduced in
all three treatment groups, compared to those recorded
in the non-suppression challenge (tied p<0.01 for all cap-
saicin concentrations, Wilcoxon signed rank test).  There
was no significant difference between the three treatment
groups at any concentration of capsaicin in the suppres-
sion challenge at baseline (p corrected for ties >0.34 for
all capsaicin concentrations), or 90 min after treatment
(p corrected for ties >0.37 for all capsaicin concentra-
tions).  The majority of subjects (41 out of 73 at base-
line, 48 out of 73 at 90 min) completely suppressed cough
at the highest capsaicin concentration.  Table 1 shows
the median total number of coughs during the suppres-
sion challenge at baseline and 90 min after treatment,
and shows that there was no significant difference in the
total number of coughs between the three treatment groups
(p corrected for ties=078 at baseline, and 0.43 90 min
after treatment).
Changes in the cough response following treatment
Changes in the cough response for each of the three
treatment groups during the suppression challenge are
illustrated in figure 2.  As with the non-suppression chal-
lenge, the total number of coughs in the suppression chal-
lenge was generally less at 90 min than at baseline.  In
the placebo group, 4 out of 21 subjects showed a reduc-
tion in the number of coughs compared with 13 out of
27 in the codeine group and 7 out of 25 in the nalt-
rexone group.  A large number of subjects (35 out of
75) showed no change in cough count from baseline.
Using the Wilcoxon signed rank test, it was found that
there was no significant difference between the total
number of coughs at baseline and 90 min after treatment
in any of the three treatment groups during the suppres-
sion challenge (tied p-value=0.78, 0.14 and 0.93 for place-
bo, codeine and naltrexone, respectively).
Discussion
The results demonstrate that cough induced by inhala-
tion of capsaicin can be voluntarily suppressed with the
majority of subjects (41 out of 73) completely suppres-
sing cough at the highest concentration of capsaicin
(3.33×10-4 M) in this study.
The present study was a parallel group design, and all
three treatment groups were well-balanced before treat-
ment with no significant difference between the three
groups for any of the cough challenges.  Following treat-
ment with placebo, codeine (50 mg) or naltrexone (50
mg), there was no significant difference between the three
treatment groups when comparing the median coughs at
each concentration of capsaicin and the median total num-
ber of coughs for each challenge unit.
When comparisons were made within groups before
and after treatment, only the codeine group showed a
significant reduction in the cough response for the non-
suppression challenge.  However, this effect of codeine
was very small, and when comparisons were made across
groups there was no significant difference between the
three groups.  Some reduction in cough response due to
a placebo effect and due to training and adaptation to
the cough stimulus would be expected, and this might
account for the significant result obtained after treatment
with codeine.  Capsaicin-induced cough may also be sub-
ject to tachyphylaxis for long periods of inhalation up to
1 min [6], but this is not a significant effect in relation
to the short periods of inhalation used in this study [7].
Similarly, there should be no carry-over effects of suc-
cessive within-days challenges, since we have shown in
a previous study (Hutchings et al. unpublished data) that
there was no significant difference between challenges
performed on the same day.  However, since the results
were compared across groups (i.e. with placebo), any
tachyphylaxis or carry-over effects would be controlled.
The failure to show any significant difference between
the three groups on capsaicin challenge does not support
the hypothesis that the opioid agonist codeine would
reduce cough and the opioid antagonist naltrexone would
increase cough due to the involvement of endogenous
opioids in the cough reflex.
In a study of this kind, it is impossible to determine
how voluntary suppression of cough occurs.  It may be
that the cough reflex is suppressed secondarily to an
altered respiratory pattern.  This seems unlikely, how-
ever, since volunteers were instructed not to hold their
breath and to maintain a normal breathing pattern.  Since
respiratory rhythm was not monitored, however, we can-
not be completely sure that normal respiration was main-
tained.  In addition, there appears to be no evidence that
altered blood gases or respiratory rates have any effect
on the cough reflex.  Similarly, if the treatments used
affected the respiratory centres, we may have been more
likely to see varying results in the different treatment
groups.  It has also been stated [8] that it is unlikely that
coughing is depressed by an action on the respiratory
centres themselves, and it was demonstrated that anaes-
thesia strongly inhibited respiration without blocking
the cough reflex, whereas, antitussives could prevent
coughing with little respiratory depression.
A negative result is always difficult to interpret, as it
is necessary to ensure that the methodology of the study
is sufficiently reliable to adequately test the hypothesis
H.A. HUTCHINGS, R. ECCLES718
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Fig. 2.  –  Changes in the number of coughs to capsaicin after treat-
ment in the suppression challenge.  Data represent the changes in cough
response in the placebo, codeine or naltrexone treated groups and were
obtained by subtracting the total number of coughs in the suppression
challenge at baseline from the total number of coughs in the suppres-
sion challenge 90 min after treatment.
under scrutiny.  Capsaicin inhalation was used to pro-
duce cough, and although it could be argued that dif-
ferent peripheral sensory receptors are involved from
those in natural cough, the central control mechanism for
the cough reflex is believed to be the same for all types
of cough.  If opioid agonists are believed to inhibit cough
by a central inhibition, one would expect all forms of
cough to be affected.  The lack of effect of codeine and
naltrexone in the present study cannot, therefore, be
explained by some mechanism of cough which is spe-
cific to capsaicin.
The doses of the drugs used in this study were above
the usual therapeutic doses, the subjects were fasted prior
to treatment, and cough measurements were taken 90
min after treatment to ensure maximal plasma drug lev-
els for both drugs.  Indeed, two volunteers were exclu-
ded from the study analysis due to nausea and vomiting.
This indicates that the drugs were adequately absorbed
and were acting at the limit of the therapeutic range.  The
negative result cannot, therefore, be explained by inade-
quate dosing or absorption of the drug treatments.
Coughs were measured in the present study as fre-
quencies, and although neither codeine nor naltrexone
showed any change in cough frequency after treatment,
it is possible that the drugs influenced some other cough
parameter, such as latency or intensity.
Single-breath inhalations of capsaicin were used in this
study, and this causes an immediate short-lived irritation
of receptors.  Since the effect was very rapid, it may be
insufficient to activate the endogenous opioid systems.
Thus, no effect would be seen after naltrexone treatment.
When endogenous opioid systems are activated, the effects
of opioid antagonists on endogenous opioids become
measurable [1].  It may, therefore, be possible to design
a future study, whereby inhalations of capsaicin over
longer periods are used, or to study the effects of opi-
oid agonists and antagonists on cough resulting from
acute upper respiratory tract infection, where an on-
going or more prolonged receptor irritation is seen.
It may be that endogenous opioids are not involved in
cough suppression, and that other CNS neurotransmit-
ters, such as serotonin or gamma-amino butyric acid
(GABA)-b agonists are involved [9–11].  Again, this
introduces a whole new area of study.
Further studies are required to examine our hypothe-
sis in more detail.  But, at present, the results of this
study seem to indicate that opioid systems are not acti-
vated in the voluntary suppression of capsaicin-induced
cough, and that both codeine, a well-established anti-
tussive treatment acting as an opioid agonist, and nal-
trexone, an opioid antagonist, have no effect on the cough
reflex or the ability to voluntarily suppress cough indu-
ced by capsaicin inhalation.
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